TEPKINLY 4 mg/0.8 ml, solution for injection bottle, 0.8 ml
Active ingredients: ÉPCORITAMAB
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injectionbottle, 0.8 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TEPKINLY 4 mg/0,8 mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon en verre de 0,8 mL
- Marketing authorisation holder
- ABBVIE DEUTSCHLAND (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 2 Nov 2023
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69520409CIP75509695CIP133400955096955Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉPCORITAMABsolution | 4 mg · un flacon de 0,8 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.